Skip to main content

Research Repository

Advanced Search

Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson–Gilford progeria syndrome fibroblasts

Bikkul, Mehmet U.; Clements, Craig S.; Godwin, Lauren S.; Goldberg, Martin W.; Kill, Ian R.; Bridger, Joanna M.

Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson–Gilford progeria syndrome fibroblasts Thumbnail


Authors

Mehmet U. Bikkul

Craig S. Clements

Lauren S. Godwin

Ian R. Kill

Joanna M. Bridger



Abstract

Hutchinson–Gilford progeria syndrome (HGPS) is a rare and fatal premature ageing disease in children. HGPS is one of several progeroid syndromes caused by mutations in the LMNA gene encoding the nuclear structural proteins lamins A and C. In classic HGPS the mutation G608G leads to the formation of a toxic lamin A protein called progerin. During post-translational processing progerin remains farnesylated owing to the mutation interfering with a step whereby the farnesyl moiety is removed by the enzyme ZMPSTE24. Permanent farnesylation of progerin is thought to be responsible for the proteins toxicity. Farnesyl is generated through the mevalonate pathway and three drugs that interfere with this pathway and hence the farnesylation of proteins have been administered to HGPS children in clinical trials. These are a farnesyltransferase inhibitor (FTI), statin and a bisphosphonate. Further experimental studies have revealed that other drugs such as N-acetyl cysteine, rapamycin and IGF-1 may be of use in treating HGPS through other pathways. We have shown previously that FTIs restore chromosome positioning in interphase HGPS nuclei. Mis-localisation of chromosomes could affect the cells ability to regulate proper genome function. Using nine different drug treatments representing drug regimes in the clinic we have shown that combinatorial treatments containing FTIs are most effective in restoring specific chromosome positioning towards the nuclear periphery and in tethering telomeres to the nucleoskeleton. On the other hand, rapamycin was found to be detrimental to telomere tethering, it was, nonetheless, the most effective at inducing DNA damage repair, as revealed by COMET analyses.

Citation

Bikkul, M. U., Clements, C. S., Godwin, L. S., Goldberg, M. W., Kill, I. R., & Bridger, J. M. (2018). Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson–Gilford progeria syndrome fibroblasts. Biogerontology, 19(6), 579-602. https://doi.org/10.1007/s10522-018-9758-4

Journal Article Type Article
Acceptance Date May 30, 2018
Online Publication Date Jun 15, 2018
Publication Date Dec 1, 2018
Deposit Date Nov 22, 2018
Publicly Available Date Nov 22, 2018
Journal Biogerontology
Print ISSN 1389-5729
Electronic ISSN 1573-6768
Publisher Springer
Peer Reviewed Peer Reviewed
Volume 19
Issue 6
Pages 579-602
DOI https://doi.org/10.1007/s10522-018-9758-4

Files

Published Journal Article (2 Mb)
PDF

Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/

Copyright Statement
© The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.







You might also like



Downloadable Citations